KENNY PADRON: Open Payments
NPI 1205537446 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,580 in 173 payments from 22 companies in 2025. Trend: 2023 $592 · 2024 $2,915 · 2025 $4,580
Food & beverage: $4,381Education: $198
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 19 | $820 |
| ABBVIE INC. | 44 | $740 |
| Galderma Laboratories, L.P. | 14 | $393 |
| Regeneron Healthcare Solutions, Inc. | 12 | $363 |
| GENZYME CORPORATION | 10 | $363 |
| Novartis Pharmaceuticals Corporation | 7 | $289 |
| PFIZER INC. | 14 | $275 |
| Arcutis Biotherapeutics, Inc. | 10 | $272 |
| Janssen Biotech, Inc. | 7 | $230 |
| LEO Pharma Inc. | 5 | $138 |
Products named: Bimzelx, DUPIXENT, RINVOQ, NEMLUVIO, CIBINQO, Zoryve, SKYRIZI, TREMFYA.
Industry payments across GA — which companies pay providers there.
